Literature DB >> 31660014

Transitioning to Fixed-Ratio Combination Therapy: Five Frequently Asked Questions Health Care Providers Should Anticipate From Their Patients.

Ian Blumer1,2, Lucia M Novak3, Steven Edelman4, Tricia Santos Cavaiola5.   

Abstract

Entities:  

Year:  2019        PMID： 31660014      PMCID： PMC6794219          DOI： 10.2337/cd18-0102

Source DB:  PubMed          Journal:  Clin Diabetes        ISSN： 0891-8929


× No keyword cloud information.
  13 in total

Review 1.  Fixed-ratio combination therapy for type 2 diabetes: the top ten things you should know about insulin and glucagon-like peptide-1 receptor agonist combinations.

Authors:  Ian Blumer; Jeremy H Pettus; Tricia Santos Cavaiola
Journal:  Postgrad Med       Date:  2018-03-20       Impact factor: 3.840

2.  Contribution of liraglutide in the fixed-ratio combination of insulin degludec and liraglutide (IDegLira).

Authors:  John B Buse; Tina Vilsbøll; Jerry Thurman; Thomas C Blevins; Irene H Langbakke; Susanne G Bøttcher; Helena W Rodbard
Journal:  Diabetes Care       Date:  2014-08-11       Impact factor: 19.112

Review 3.  How pharmacokinetic and pharmacodynamic principles pave the way for optimal basal insulin therapy in type 2 diabetes.

Authors:  S Arnolds; B Kuglin; C Kapitza; T Heise
Journal:  Int J Clin Pract       Date:  2010-07-05       Impact factor: 2.503

Review 4.  IDegLira: Redefining insulin optimisation using a single injection in patients with type 2 diabetes.

Authors:  Eugene Hughes
Journal:  Prim Care Diabetes       Date:  2016-01-14       Impact factor: 2.459

5.  Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial.

Authors:  Ildiko Lingvay; Federico Pérez Manghi; Pedro García-Hernández; Paul Norwood; Lucine Lehmann; Mads Jeppe Tarp-Johansen; John B Buse
Journal:  JAMA       Date:  2016-03-01       Impact factor: 56.272

Review 6.  GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus.

Authors:  Juris J Meier
Journal:  Nat Rev Endocrinol       Date:  2012-09-04       Impact factor: 43.330

7.  Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial.

Authors:  Michael Nauck; Manfredi Rizzo; Andrew Johnson; Heidrun Bosch-Traberg; Jesper Madsen; Bertrand Cariou
Journal:  Diabetes Care       Date:  2016-06-16       Impact factor: 19.112

8.  Rates of hypoglycaemia are lower in patients treated with insulin degludec/liraglutide (IDegLira) than with IDeg or insulin glargine, regardless of the hypoglycaemia definition used.

Authors:  Paul Norwood; Roger Chen; Elmar Jaeckel; Ildiko Lingvay; Henrik Jarlov; Lucine Lehmann; Simon Heller
Journal:  Diabetes Obes Metab       Date:  2017-07-10       Impact factor: 6.577

9.  Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin-naïve people with Type 2 diabetes: the DUAL IV trial.

Authors:  H W Rodbard; B W Bode; S B Harris; L Rose; L Lehmann; H Jarlov; J Thurman
Journal:  Diabet Med       Date:  2016-10-07       Impact factor: 4.359

Review 10.  Rationale for, Initiation and Titration of the Basal Insulin/GLP-1RA Fixed-Ratio Combination Products, IDegLira and IGlarLixi, for the Management of Type 2 Diabetes.

Authors:  Virginia Valentine; Jennifer Goldman; Jay H Shubrook
Journal:  Diabetes Ther       Date:  2017-07-18       Impact factor: 2.945
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.